Karuna Therapeutics, Inc. financial data

Industry
Pharmaceutical Preparations
Location
99 High Street, 26 Th Floor, Boston, MA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2023 - Feb 22, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.12K % +9.36%
Debt-to-equity 4.11 % -0.24%
Return On Equity -31.6 % +9.32%
Return On Assets -30.4 % +9.28%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.2M shares +2.02%
Common Stock, Shares, Outstanding 38.1M shares +10.5%
Entity Public Float 5.87B USD +101%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 37M shares +16.9%
Weighted Average Number of Shares Outstanding, Diluted 37M shares +16.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 364M USD +62.4%
General and Administrative Expense 131M USD +72.7%
Operating Income (Loss) -495M USD -70.8%
Nonoperating Income (Expense) 61.8M USD +319%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -433M USD -57.5%
Income Tax Expense (Benefit) 1.42M USD +23533%
Net Income (Loss) Attributable to Parent -434M USD -56.9%
Earnings Per Share, Basic -11.7 USD/shares -34.2%
Earnings Per Share, Diluted -11.7 USD/shares -34.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 186M USD -25.2%
Other Assets, Current 12.5M USD +701%
Assets, Current 1.32B USD +13.9%
Property, Plant and Equipment, Net 5.42M USD +69.4%
Operating Lease, Right-of-Use Asset 15.1M USD +223%
Other Assets, Noncurrent 382K USD -11%
Assets 1.34B USD +14.9%
Accounts Payable, Current 6.78M USD +185%
Employee-related Liabilities, Current 15.1M USD +26.7%
Accrued Liabilities, Current 41.6M USD +42.1%
Liabilities, Current 68.1M USD +101%
Operating Lease, Liability, Noncurrent 13.8M USD +355%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 82M USD +121%
Retained Earnings (Accumulated Deficit) -998M USD -76.9%
Stockholders' Equity Attributable to Parent 1.25B USD +11.4%
Liabilities and Equity 1.34B USD +14.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -101M USD -102%
Net Cash Provided by (Used in) Financing Activities 442M USD +35099%
Net Cash Provided by (Used in) Investing Activities -27.5M USD -254%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 38.1M shares +10.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 314M USD
Deferred Tax Assets, Valuation Allowance 373M USD +65.2%
Deferred Tax Assets, Gross 377M USD +66%
Operating Lease, Liability 16.7M USD +213%
Payments to Acquire Property, Plant, and Equipment 714K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -430M USD -54.1%
Lessee, Operating Lease, Liability, to be Paid 44.3M USD +673%
Property, Plant and Equipment, Gross 8.53M USD +74.8%
Operating Lease, Liability, Current 2.84M USD +24.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.82M USD +202%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.04M USD +20.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +85.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.5M USD +4393%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.59M USD +121%
Deferred Tax Assets, Operating Loss Carryforwards 150M USD +41.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.7M USD
Operating Lease, Payments 641K USD +1.59%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 327K USD +31.9%
Share-based Payment Arrangement, Expense 74.6M USD +57.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%